New ADC drugs for the treatment of platinum-resistant ovarian cancer are fda fast-tracked.

Read: Mersana Therapeutics Antibody Association Drug (ADCs) XMT-1536 is FDA-granted fast-track qualification for the treatment of platinum-resistant high-level slurry ovarian cancer.
. On August 11, local time, Mersana Therapeutics, a U.S. biopharmaceutical company, announced that its antibody-coupled drug (ADCs) XMT-1536 was awarded fast-track status by the FDA for the treatment of platinum-resistant high-level slurry ovarian cancer.
these patients are platinum resistant and have received three pre-systemic treatments, or four advance systemic treatments regardless of platinum resistance.
XMT-1536 targets naPi2b, a sodium-dependent phosphate transporter protein, using the Dolaflexin ADC drug development platform to form ADC drugs that can be delivered by 10-12 DolaLock payload molecules per antibody.
NaPi2b antigens are widely expressed in ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma subsypes.
XMT-1536 is conducting a proof-of-concept Phase 1 clinical trial for patients with NaPi2b-positive tumors, including ovarian and NSCLC adenocarcinoma patients.
the trial is a multi-center clinical study that plans to recruit 120 patients.
group gave patients XMT-1536 intravenous injections every four weeks to explore dose increment and dose expansion.
main endpoints are the maximum to-to-do dose or phase 2 clinically recommended dose, with secondary endpoints including maximum observed concentration time, maximum concentration of XMT-1536, area between concentration curves, tumor shrinkage, and analysis of XMT-1536 antibodies and meso-antibodies in the blood.
, president and chief executive officer of Mersana, said we were encouraged by the FDA's decision to grant the XMT-1536 fast track eligibility.
XMT-1536 has shown welcome activity and toerability in the first phase of ovarian cancer clinical trials to date.
Mersana Therapeutics, a biopharmaceutical company focused on clinical stage drug development, is rapidly developing new ADC drugs through its unique and proprietary ADC drug development platform, with the aim of discovering high-impact, safe and toned ADC drugs to improve the chances of survival of patients fighting cancer.
's leading drug candidate, XMT-1536, was developed by Mersana through its commercially homogenized delivery platform, Dolasynthen.
company's other early projects include the B7-H4 Targeted ADC and the STING astrist ADC developed by the company's Immunosynthen platform.
Mesana has reached ADC drug discovery partnerships with several companies on the Dolasynthen platform.
Mersana is working on product line ADCS technology that uses linker to couple monoantigens with drug molecules, using antibody-specific targets to transport drug molecules to the target tissue to play a role, reducing the drug's systemic toxic side effects, improving the drug treatment window and expanding the potential of antibody therapy.
ADC drugs for ovarian cancer have not been approved worldwide, and NaPi2b will be a new target for the treatment of the disease.
source: Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for The Treatment of Patients with Platinum-resistant Ovarian Cancer.